HomeOpen Access NewsDrug Development

Drug Development

UKHSA reports rising resistance to newest antibiotics on NHS

A new study shows some bacteria have already become resistant to one of the latest antibiotics available on the NHS.

European Commission says vaccine deliveries to UK could be stopped

President von der Leyen today (17 March) said that the Commission would limit vaccine deliveries to the UK if "the situation does not change" - suggesting that the drugmaker AstraZeneca is responsible for vaccination delays in the EU.

Birth control creates higher risk of blood clots than AstraZeneca vaccine

Currently, several EU countries are suspending use of the AstraZeneca vaccine due to reports of blood clot risks - in response, people are speaking out about the higher risk of blood clots posed by contraceptive pills used globally.

How global evidence can improve outcomes for spinal patients

Everard Munting, President of EUROSPINE, explains why sharing knowledge about spinal treatments on a global scale is the most effective way to develop best practice and enable early interventions.

European Medicines Agency says AstraZeneca vaccine still safe to use

Over the weekend, the Republic of Ireland suspended their use of AstraZeneca due to reports of blood clots in Norway - in response, the European Medicines Agency (EMA) says the AstraZeneca vaccine is still safe to use.

Diphtheria slowly becomes resistant to antimicrobial treatment

There is a well-established diphtheria vaccine taken by millions of people, but researchers are now observing the disease evolving a resistance to antimicrobial treatment.

Novavax 96.4% effective against the original COVID mutation

The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.

How valuable are randomised controlled trials in reproductive medicine?

Professor Darren Griffin reflects on how patients in fertility clinics should interpret the scientific evidence base when even the experts can’t seem to agree.

Bharat Biotech COVID vaccine shows 81% efficacy at Phase Three

The Bharat Biotech COVID vaccine, COVAXIN, appears to be 81% efficient against the virus in Phase Three of clinical trials.

Scientists find that elevated neutrophils can predict severe COVID and death

Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.

Israel will now vaccinate Palestinians who have permits to work 

Israel faced international criticism on their refusal to vaccine Palestinians - now, the country will begin rolling out Pfizer shots to some Palestinians who have work permits.

FDA approves the Johnson & Johnson vaccine for use

The US Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine, with an efficacy of 86%, as the next to be rolled out across the US.

The window for convalescent plasma donation is just under two months

New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.

Pfizer vaccine can reduce COVID hospitalisation and death by 75%

Early stage data from the vaccine rollout in the UK appears to show that COVID hospitalisation and death are reduced by over 75% in people with the Pfizer vaccine.

Science needs to overcome “structural racism” to end the HIV epidemic

A new report published in The Lancet investigates why 43% of HIV deaths in 2018 happened in the Black community, with policy solutions for the ongoing HIV epidemic.

REACT study: COVID cases in hospitals “higher than at the peak of the first wave”

New data from the REACT study finds that the number of COVID cases in hospitals is higher than it was in April 2020, but that infection rates are substantially decreasing across the country.

The Johnson & Johnson COVID vaccine works with just one dose

The New Jersey-based drugmaker created a COVID-19 vaccine that works at 66% efficiency in one dose, which they have sent to the EU for approval.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders